The National Institute for Health and Care Excellence (NICE) has recommended Janssen's Tremfya as a cost-effective treatment for plaque psoriasis, Pharma Times reported on Friday.
A Final Appraisal Determination was published by the cost regulator to back the funding for the drug, which was launched in the UK in the November.
Tremfya (guselkumab) is the first biologic to selectively target interleukin (IL)-23, a key protein involved in the immune inflammatory response in psoriasis.
The Final Appraisal Determination was fast-tracked as a result of the European approval in November last year. Approval was based on Phase III trials, VOYAGE 1 and VOYAGE 2, which showed high rates of skin clearance.
Janssen has agreed a confidential patient access scheme with the Department of Health and Social Care, offering the drug to the NHS at a reduced cost.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval